Legend Biotech, a leader in cell therapy, reported that its CAR-T treatment CARVYKTI generated nearly $2 billion in sales in 2025. CARVYKTI, developed and co-promoted with Johnson & Johnson, is a one-time infusion therapy for multiple myeloma and has seen the fastest commercial launch among CAR-T therapies. This strong performance highlights Legend's pioneering role in immune cell therapies for tough diseases. The company also hosted an investor event discussing CARVYKTI's curative potential, early treatment benefits, and safety management in real-world use.
Johnson & Johnson's Phase 3 PROTEUS study shows ERLEADA (apalutamide) combined with hormone therapy before and after surgery significantly improves outcomes for high-risk localized prostate cancer patients. The treatment increased the chance of minim...
Johnson & Johnson reported that subcutaneous amivantamab, a dual EGFR and MET inhibitor, achieved a 42% overall response rate in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. More...
Johnson & Johnson's Phase 3 PROTEUS study found that combining apalutamide with hormone therapy before and after prostate cancer surgery significantly improves outcomes for high-risk localized or locally advanced prostate cancer patients. The treatme...
Johnson & Johnson announced that their drug combination RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGF...
Johnson & Johnson announced positive Phase 3 results from the MajesTEC-9 study, showing TECVAYLI (teclistamab-cqyv) significantly improves progression-free and overall survival in relapsed or refractory multiple myeloma patients treated as early as s...
